San Francisco startup Structure Therapeutics can be focusing on an oral, at the time-every day GLP-one drug called GSBR-1290—the drug surpassed Wall Avenue’s expectations in June when a mid-stage research confirmed average weight loss of about six% and it options to start A different mid-stage demo toward the end of the 12 months—that founder